Literature DB >> 28537051

Artificial Ureter in Patients with Extensive Ureteral Damage.

Mohammad Yazdani1, Amir Javid2, Mehrdad Mohammadi Sichani1, Mohammad Reza Gharaati1, Emad Yazdani1.   

Abstract

PURPOSE: loss of significant lengths of ureter when substitution with bowel or bladder fails is a disaster in urology. This study is conducted to evaluate the results of subcutaneous nephron-vesical bypass (SNVB) in ureteral damage of different etiologies.
MATERIALS AND METHODS: Seventeen SNVB were employed in patients with ureteral injuries. We employed a device consisted of an internal silicone tube covered by a coiled PTFE tube to replace the ureter. This is called artificial ureter (AU). Proximal end of the AU was introduced in the kidney percutaneously, the tube was passed through a subcutaneous tunnel, while the distal end was inserted in the bladder through a small suprapubic incision.
RESULTS: Follow-up ranged from six months to ten years. We removed the prosthetic ureter in one patient due to gross hematuria two months after insertion. One of the patients was reoperated two days after the procedure because of urinary leakage. In all other patients, the procedure was safe and effective.
CONCLUSION: Subcutaneous nephron-vesical bypass is a safe and appealing alternative to a nephrostomy tube. This is a permanent device with no need for exchange. The technique can be applied in ureteral injuries due to various causes.

Entities:  

Mesh:

Year:  2017        PMID: 28537051

Source DB:  PubMed          Journal:  Urol J        ISSN: 1735-1308            Impact factor:   1.510


  2 in total

1.  Spotlight - Management of pyelovesical bypass device stones.

Authors:  Ahmad Almarzouq; Sero Andonian
Journal:  Can Urol Assoc J       Date:  2018-02-06       Impact factor: 1.862

2.  Use of a subcutaneous ureteral bypass device for treatment of bilateral proximal ureteral injury in a 9-month-old cat.

Authors:  Joseph A Sapora; Robert J Hardie; Natashia Evans
Journal:  JFMS Open Rep       Date:  2019-03-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.